Female and smokers are associated with acute and long COVID-19 symptoms among 32,528 vaccination individuals: a cross-sectional and nationwide study from China

doi:10.21203/rs.3.rs-3436340/v1

Download PDF

Research Article

Female and smokers are associated with acute and long COVID-19 symptoms among 32,528 vaccination individuals: a cross-sectional and nationwide study from China

https://doi.org/10.21203/rs.3.rs-3436340/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 01 Aug, 2024

Read the published version in BMC Public Health →

You are reading this latest preprint version

Backgrounds

To our knowledge, there is no available nationwide data on omicron symptom patterns in China mainland. We aim to determine the acute and long COVID-19 symptoms in the omicron-dominant period and to evaluate its association with age, sex and smoking status.

Methods

We designed a cross-sectional nationwide study and data about self-reported symptoms were collected by an online platform named Wenjuanxing. Eligible participants were aged 25–65 years and were symptomatic. To improve the representativeness of sample size, the ratios of the number of people of different ages and genders were weighted by the data from the Seventh National Census (2020 years), and validated by a published nationwide representative study through comparing smoking rates. Descriptive analysis was conducted to report information on demographic characteristics, diagnosis ways and duration time, acute symptoms, hospitalization, severity and long COVID-19 symptoms. And, multivariate Logistic regression models were used to explore the effect of age, sex and smoking on acute and long COVID-19 symptoms.

Results

A total of 32,528 individuals diagnosed as COVID-19 infection from October 1, 2022 to February 21, 2023 were included. The top three acute symptoms of COVID-19 infection were fever (69.90%), headache (62.63%), sore throat (54.29%). The rates of hospitalization within 7 days, symptoms disappear within 21 days were 3.07% and 68.84%, respectively. Among 3983 COVID-19 patients with 3 months or more time difference between first infection and participation into the study, the long COVID-19 rate was 19.68% and the primary symptoms were muscle weakness (19.39%), headache (17.98%) and smell/taste disorder (15.18%). Compared with male and never smokers, female and current smokers were risk factors for each acute CVOID-19 symptoms, and also had a higher risk for fatigue among long COVID-19 symptoms. Lastly, female and current smokers also were related with more number of symptoms during acute infection period.

Conclusions

Omicron variant to be milder in terms of severity in China mainland. And, more attention should be given to high-risk population (current smokers and women) to control disease burden caused by COVID-19.

Omicron

COVID-19 symptoms patterns

China mainland

Smoking

Female

The global pandemic caused by COVID-19 has resulted in enormous economic and health burden. As of 3 May 2023, there have been about 765 million confirmed cases of COVID-19 (coronavirus disease 2019), including about 7 million deaths around the world, reported to World Health Organization (WHO)[1]. More than three years into the global pandemic, WHO has identified several variants of the virus including: alpha, beta, gamma, delta, and omicron[2], which differ in transmissibility, disease symptoms, and severity of symptoms[3]. To date, Omicron including subvariants are generally considered the most important virus variant, given the current prevalence rate among general public[4, 5]. Although most cases caused by this variant of concern resolve within two to four weeks of the initial symptoms’ appearance[6], emerging evidence shows virus variants potentially affect the long term health outcomes after infection, often referred to as “long COVID” outcomes[7–9].

COVID-19 is not a disease that can be ignored, although on May 5, 2023, Tan Desai, Director General of the WHO, announced that the COVID-19 epidemic was no longer listed as a public health emergency of international concern (PHEIC)[10]. In other words, the end of the pandemic does not mean that all countries or regions in the world are no longer threatened by the epidemic at the same time. For example, COVID-19 might become a long-term health burden for the United States, because more than 1000 people still die each week even at the current COVID-19 epidemic low point[11]; in addition, the epidemic in Southeast Asia is currently in a rebound period due to the impact of the new Omicron strain. In the past few weeks, China has shown signs of other Omicron virus strains such as the XBB strain, which may indicate that a second wave of the epidemic is coming[12].

Better understanding of symptoms and long-term health effect of variants of concern may help clinicians, researchers, and policy advisors plan for diagnosis, treatment, and public health efforts of COVID-19. On Nov 26, 2021, Omicron was firstly designated a variant of concern by WHO[13], which has been identified in 210 countries and is now the most prevalent lineage globally[14]. Compared with previously dominant delta variant, the clinical severity, such as hospitalisations and deaths, of omicron infection is lower[15–21]. However, previous studies has indicated that age and vaccination status trigger different clinical presentation for Omicron infection[19, 22]. On the other hand, the cumulative evidence of latest studies also have established the primary symptoms of long COVID, including fatigue, shortness of breath, cough, cognitive impairment and anosmia[6, 23, 24]; and some risk factors have already been identified, such as older age, obesity, history of chronic diseases (cardiovascular disease, chronic lung disease, kidney disease and diabetes) and female sex[25–33].

Representative population-based studies on acute/long symptoms of Omicron infection are scarce in Chinese mainland. On May 23, 2023, we searched PubMed with the terms ((“SARS-CoV-2”) AND (“omicron”) AND (“symptoms”) AND (“China mainland”)), with no date or language restrictions. We screened all papers by reading full text, and found that no national data on omicron symptoms was available in China mainland. This might be related with the fact that only a small portion of the people in Chinese mainland were exposed to SARS-CoV-2 prior to November 2022, when ‘Dynamic zero-COVID’ policy—including mass testing, population vaccination, quarantining and travel restrictions—to protect hundreds of thousands of people from infection and deaths[34]. From November 11 to December 7, 2022, more flexible COVID-19 control measures were conducted, for example, to encourage voluntary stay-at home quarantine, gradual replacement of nucleic acid screening by antigen detection, and the lift of travel restrictions, et al[35]. On December 26, 2022, the National Health Commission announced that the COVID-19 would be changed from category B infectious disease with management of category A to category B disease with management of category B starting from January 8, 2023[36].

Therefore, to provide data about acute and long-COVID symptoms in individuals in Chinese mainland and explore the effect of risk factors such as sex, age and smoking status, we conducted a nationwide study and collected information on infected patients by online questionnaire survey from January 28 to February 21, 2023.

Study design

We conducted a nationwide and cross-sectional study, although sample size was not rigorously calculated. Firstly, the 31 provinces/municipalities/autonomous regions of China are divided into five geographical divisions, namely, East China, South China, Central China, North China, West China. Then, according to data from the Seventh National Census (2020 years), the ratios of the number of people of different ages and genders in each divisions to the total number of people in China were viewed as weighted rates of sample size (Appendix Table 1). And, the weighted rates were as the basis for sample size allocation. Lastly, to validate the representativeness of this sampling method, we compared the smoking rates in this study with the rates in a published nationwide representative study, concluding that our participants were nationally representative (Appendix Table 2).

Table 1

Characteristics of COVID-19 infected patients included into analysis
	Total (N = 32,528)	No. (%)
Areas
North China	6076	18.68
South China	4481	13.78
West China	6951	21.37
East China	9995	30.73
Central China	5025	15.45
Age group, years
25–34	8559	26.31
35–44	7687	23.63
45–54	9293	28.57
55–65	6989	21.49
Sex
Male	16652	51.19
Female	15876	48.81
Smoking
Current smoker	8707	26.77
Former smoker	1121	3.45
Never smoker	22700	69.79
Education
Primary school or lower	1059	3.26
Middle school	3586	11.02
High school	7432	22.85
College or higher	20451	62.87
Marriage status
Unmarried	12173	37.42
Married	17587	54.07
Divorced	2768	8.51
Any of the following physical diseases	14187	43.61
cardiovascular diseases	4473	13.75
diabetes	3022	9.29
chronic respiratory diseases	3793	11.66
Digestive system diseases	2911	8.95
chronic liver disease	1654	5.08
chronic kidney disease	899	2.76
malignancy	636	1.96
Hematological disease	539	1.66
Allergic diseases	1995	6.13
Anxiety or Depression	1928	5.93
Infectious status were determined by which testing
Self-reported Symptoms	14228	43.74
Antigen detection tests	11879	36.52
Nucleic acid based tests	6421	19.74
Vaccinated for COVID-19
Two vaccine doses	23525	72.32
Three vaccine doses	9003	27.68
Hospitalization within 7 days	998	3.07
Disappear within 21 days	22393	68.84
long COVID-19	784	19.68*
*: Only 3983 COVID-19 patients were followed up for 3 months or more

Table 2

Odds ratios (OR) and 95% confidence intervals (95% CI) for the associations of age, sex, smoking status and severity of acute phase symptoms
	Model 1			Model 2
	OR	95% CI	P value	OR	95% CI	P value
Age group, years
25–34	—	—
35–44	1.10	1.04, 1.18	< 0.01	1.10	1.03–1.17	< 0.01
45–54	0.94	0.88, 1.00	0.04	0.92	0.87–0.98	0.01
55–65	0.80	0.75, 0.86	< 0.01	0.80	0.75–0.86	< 0.01
Sex
Male	—	—
Female	1.89	1.79, 2.00	< 0.01	1.16	1.11–1.22	< 0.01
Smoking
Current smoker	—	—
Former smoker	0.74	0.65, 0.84	< 0.01	0.80	0.70–0.90	< 0.01
Never smoker	0.35	0.33, 0.37	< 0.01	0.50	0.47–0.52	< 0.01
*: Model 1: Univariate Logistic regression model;
Model 2: Multivariate Logistic regression model, adjusting for educational level, marriage, BMI, history of chronic diseases and vaccination status;

Study population

The participants were recruited from January 28 to February 21, 2023, and they were required to complete an electronic questionnaire on a survey platform named Wenjuanxing. A total of 88,746 infected individuals participated into the online survey. Of these, 22,361 participants were were excluded, including 18,019 participants completed the questionnaire within 2 minutes and 4,342 participants completed the same questionnaire by being submitted multiple times by a user. Of the remaining 66,537 participants, we further excluded 10,021 individuals, including 3206 people aged < 25 or > 65 years and 6815 people diagnosed as COVID-19 infection prior to October 1, 2022. Finally, from the remaining 56,516 subjects, 32,528 individuals were selected on the basis of weighted sample size rates, which were included into the analysis database. The flowchart was seen in Fig. 1.

Ethical considerations

The study was approved by the institutional review board of the China-Japan Friendship Hospital (2022-KY-183-1). This study complied with the Declaration of Helsinki. Informed consent was obtained for each participant. Study data of individuals are anonymous and there is no compensation for all participants.

Variables

Online surveys included questions on demographic characteristics (gender, age, educational level, marriage and area); history of chronic disease (cardiovascular diseases, cancers, diabetes and chronic respiratory diseases, etc); smoking and vaccination status. Secondly, questions on COVID-19 infection including date and ways of diagnosis, symptoms and duration of acute phase, and hospitalization or not. Thirdly, questions on long COVID-19 including infection numbers, symptoms and duration. The definition of long COVID-19 in our study is consistent with the definition of World Health Organization (WHO), namely that the condition occurs after a history of probable or confirmed SARS-CoV-2 infection[37]. Symptoms usually occur 3 months from the onset of acute COVID-19 symptoms, last for at least 2 months and cannot be explained by an alternative diagnosis. Finally, detailed information on the symptoms are listed in Results section below.

Statistical analysis

Continuous variables were summarized as mean and standard deviation and categorical variables as frequencies and percentages. We listed the symptoms distribution during acute phase in all COVID-19 infection patients, and the distribution by sex, age, smoking status. Furthermore, we also analyzed the long COVID-19 symptoms distribution among the symptomatic population, and the distribution by sex, age, smoking status.

In addition, for each of the individual acute phase symptoms, a series of multivariate Logistic regression models were used to explore the association between each risk factor and symptoms among all infectious patients. For long COVID-19 symptoms, regression models were also built to provide odds ratios (ORs) for each of the risk factors, and symptomatic patients were served as observation group and patients with no report of symptoms as control group. In our study, age groups, sex, smoking status, educational level, marriage, BMI, history of chronic diseases and vaccination status were included into the multivariate Logistic regression models as risk factors.

Lastly, we divided all subjects into severely (4 symptoms or more) and lightly (less than 4 symptoms) symptomatic groups, according to the number of symptoms during acute infection phase (the median value was 4). We conducted univariate and multivariate Logistic regression models to explore the relationship between risk factors and the severity of symptoms during the acute infection period, respectively. All statistical analyses were performed in R software, version 4.2.1.

Participants information

As shown in Table 1, among 32528 COVID-19 patients, there were 6076 (18.68%), 4481 (13.78%), 6951 (21.38%), 9995 (30.73%) and 5025 (15.45%) subjects from North China, South China, West China, East China, Central China, respectively. The proportions of population number in aged 25–34, 35–44, 45–54 and 55–65 were 26.31%, 23.63%, 28.57% and 21.49%, and in male was 51.19%, respectively. Appendix Table 2 shown that smoking rates by age groups and sex were similar to a previous representative and nationwide study, and the overall smoking rate is 26.77%. More than half of participants were married (54.07%), and had a college or higher (62.87%). 14187 (43.61%) had at least one underlying disease and the most common physical diseases were cardiovascular diseases (13.75%), chronic respiratory diseases (11.66%) and diabetes (9.29%). 56.26% of participants infectious status were determined by nucleic acid based tests (19.74%) or antigen detection tests (36.52%), and 72.32% of all subjects have received two dose of COVID-19 vaccine.

Clinical patterns and influencing factors among all acute COVID-19 patients

Figure 2A present the acute symptoms stratified by sex, age and smoking status. The most common symptoms during the acute phase of infected individuals were fever (69.90%), headache (62.63%), sore throat (54.29%), fatigue (50.81%), cough (35.14%), sleep disturbance (35.38%), mood disorders (37.31%) and joint pain (20.60%). Of the remaining symptoms, the prevalence were lower than 20.00%, such as rhinobyon (19.65%), smell/taste disorder (17.82%), runny nose (17.37%), muscle weakness (16.70%), dyspnea (7.38%), nausea (6.89%), palpitation (5.94%), diarrhea (5.16%) and sore eye (4.07%). Additionally, the rates of hospitalization within 7 days and symptoms disappear within 21 days were 3.07% and 68.84%, respectively (Table 1).

We also did sub-analyses assessing the symptoms prevalence by sex, age and smoking status, and reported that the prevalence of fever, sore throat, fatigue, muscle weakness, smell/taste disorder, rhinobyon, runny nose, nausea, mood disorders were significantly different among sex or age groups. Then, in male versus female, another the difference in symptom rates of palpitation, joint pain and dyspnea; there were sleep and disturbance cough in 25–44 years versus 45–65 years. Lastly, the reported rates of all acute symptoms among smokers were significantly higher than those among non-smokers (Fig. 2A).

We conducted multivariable logistic regression analysis and found that non-smokers had a lower proportion rate of each acute symptoms than smokers, as shown in Fig. 3A. Of the remaining 16 symptoms (except for fever), female had a higher risk than male. And age was a risk factor for acute symptoms of fever, sore throat, fatigue, cough, headache, smell/taste disorder, rhinobyon and runny nose, but not for symptoms of muscle weakness, sore eye, diarrhea, nausea, palpitation, joint pain, dyspnea, sleep disturbance and mood disorders.

Relationship between age, sex, smoking status and severity of acute phase symptoms

We also explored the influencing factors of severity of acute phase symptoms and results were shown in Table 2. After adjusting for educational level, marriage, BMI, history of chronic diseases and vaccination status, multivariable logistic regression results indicated that female had a higher risk of serious acute phase symptoms (OR 95%CI: 1.16, 1.11–1.22), while non-smokers had a lower risk (OR 95%CI: 0.50, 0.47–0.52). Finally, compared with individuals aged 25–34 years, people aged 35–44 years was a risk factor for serious acute symptoms (OR 95%CI: 1.11, 1.03–1.17) but those aged 45–54 years and 55–65 years were protective factors (OR 95%CI: 0.92, 0.87–0.98, OR 95%CI: 0.80, 0.75–0.86, respectively).

Clinical patterns and influencing factors among long COVID-19 individuals

Among 3983 COVID-19 patients, the date difference between first infection and participation into this study was 3 months or more, and the rates of long COVID-19 in Chinese population was 19.68% (784/3983), as shown in Table 1. Figure 2B showed the distribution of long COVID-19 symptoms stratified by sex, age and smoking status. The frequently observed symptoms were muscle weakness (19.39%), headache (17.98%), smell/taste disorder (15.18%), fatigue (13.39%), rhinobyon/runny nose (11.73%), sore throat (11.10%), memory impairment (10.08%) and mood disorders (10.02%). Moreover, the prevalence of symptoms of lumbago, cough, dyspnea, hearing loss, sleep disturbance, sore eye, palpitation, joint pain and hair loss were 9.44%, 9.31%, 9.06%, 8.93%, 8.67%, 8.55%, 7.02%, 6.76% and 4.34%, respectively.

The results of subgroup analysis suggested that there were no significant differences in symptoms distribution between male and female, smokers and non-smokers. In addition, the joint pain and smell/taste disorders were significantly more prevalent among individuals aged 25–44 years, while mood disorders were more common among those aged 55–65 years (Fig. 2B).

Figure 3B present the effect of age, sex, smoking status on the long COVID-19 symptoms incidence rates. Compared with patients aged 25–34 years, older age groups (45–54 years, 55–65 years) had higher incidence risks for rhinobyon/runny nose, fatigue and mood disorders. In addition, non-smokers was a protective factor for fatigue (OR 95%CI: 0.58, 0.35–0.95). Finally, female was also associated with an increased risk of fatigue.

Utilizing the self-reported data of a nationwide representative COVID-19 patients in China, our study firstly reported the acute and long symptoms of COVID-19 infection, as well as explored the effects of age, gender and smoking status in the Chinese population. Data showed that the top three acute symptoms of COVID-19 infection were fever, headache and sore throat, for which age groups, gender and smoking status were influencing factors. The rates of hospitalization within 7 days, symptoms disappear within 21 days and long COVID-19 were 3.07%, 68.84% and 19.68%, respectively. Additionally, the primary symptoms of long COVID-19 were muscle weakness and headache, and female and smoking were risk factors for fatigue. Lastly, female, current smokers and those aged 45–54 years and 55–65 years (individuals aged 25–34 years as reference group) were related with more number of symptoms during acute infection period.

In general, our findings on the clinical patterns of acute/long COVID-19 infection in Chinese population were consistent with prior studies from other countries. For acute symptoms of Omicron, the most frequently reported symptoms in our study were fever (69.90%), headache (62.6%), sore throat (54.3%), fatigue (50.8%) and cough (35.1%), while results from the ZOE COVID Study showed that they were runny nose (76.5%), headache (74.7%), sore throat (70.5%), sneezing (63.0%) and persistent cough (49.8%), respectively[19]. Although the main symptoms were similar in the above two studies, the incidence of symptoms was lower in the Chinese study. In addition, the evidence that the clinical severity of infection is lower for omicron than for previously dominant delta variant has been well established[20]. Data from China further booster the evidence that omicron variant to be milder in terms of severity. In our study, the rates of hospital admission within 7 days and recovered within 21 days were 3.1% and 68.8%, respectively. Accordingly, there were 1.9% and 25.0% in the ZOE COVID study. However, the difference in absolute values may be related to population vaccination. The fact that COVID-19 vaccination could promote the recovery of COVID-19 symptoms and reduce intrinsic severity such as hospitalization and death attributable to COVID-19 is indisputable. All individuals in our study were the vaccinated population with at least two doses, while studies from other countries included unvaccinated population[19, 20]. By December 13, 2022, over 90% of the population in China mainland were vaccinated by at least two doses of inactivated vaccines. Given the small sample size of unvaccinated population, there were too many difficulties in including those without vaccination, so our study only focused on the vaccination population.

We found that among Omicron infected individuals, female and smokers had higher proportion of acute symptoms than male and non-smoker. In early period of the outbreak of epidemic, data suggested that severe or deceased COVID-19 cases were more common in male[38–40]. But the high absolute number of male might be related with more exposure chance for COVID-19 viruses, such as frequent social activities and long business trips. However, in the omicron-dominant period, both male and female would face the same risk of infection because non-pharmaceutical public health intervention (NPI) measures—including quarantining and travel restriction—has been revised based on the fact that omicron variant seems to be much more transmissible[18, 21, 41, 42] and less severe[43] than previous variants and high population vaccination rates[35, 36, 44]. Therefore, higher proportion and more number of acute symptoms for female provided a clue that female should be given more attention during omicron prevalence. Similarly, our data also indicated that smokers should be viewed as high risk population susceptible to Omicron symptoms. Extensive previous research has shown smokers were at greater risk of developing severe disease after infection than are non-smokers such as hospital admission, ICU admission and death[45–48], although cigarette smoking on COVID-19 infection are conflicting[49]. This might be related with the evidence that smoking induces substantial lung injury, because harmful substances in tobacco smoke damage epithelial cells and further compromise the epithelial barrier and mucociliary clearance[50]. Lastly, prior evidence have established that disease severity, hospital admission, and death of COVID-19 were dependent on age[22]. In our study, the highest number of Omicron symptoms were reported in the 35–44 years subgroup and Omicron had age-specific symptoms pattern, which might be helpful to better understanding of the different courses in the age groups.

Our data showed that the incidence of long COVID-19 symptoms at 3 months after a first Omicron infection was 19.68% in China mainland, and the main symptoms were muscle weakness, headache, smell/taste disorder and fatigue. The long COVID-19 rates were varied in different studies, which might be related with observation periods of sequelae of COVID-19, virus variants and vaccination status. For example, the UK’s Office for National Statistics found that of triple-vaccinated participants, the socio-demographically adjusted prevalence of self-reported long COVID four to eight weeks after a first COVID-19 infection was 8.5% for Delta and 8.0% for Omicron BA.1. and 9.1% for Omicron BA.2[51]. When they extended follow-up period to 12 to 16 weeks, there were 5.0% for Delta, 4.5% for Omicron BA.1 and 4.2% for Omicron BA.2, respectively. In addition, data from a multicenter prospective cohort study suggested that among the COVID-positive cohort, self-reported prolonged symptoms at 3 months were 52.6% in the pre-Delta group, 41.5% in the Delta and 41.5% in the Omicron, respectively, but not all participants of this study have vaccination (18.4% in the pre-Delta, 74.1% in the Delta and 98.4% in the Omicron)[52]. Moreover, in Eastern India, researchers found that 29.2% self-reported having long COVID symptoms 4 weeks after diagnosis[53], however they also found that the prevalence on long COVID after infection with only Omicron variant was 8.2%[54]. Lastly, prior studies have also supported that vaccination could reduce the risk of the post-acute sequelae of COVID-19[55–57]. Findings from a nationwide cohort study indicated that compared with unvaccinated patients, those with vaccination had significantly lower risk for dyspnoea up to three months after infection[6]. This is in accordance with studies showing that vaccination before COVID-19 breakthrough infection partially reduced the risk of post-acute sequalae[55]. For long COVID-19 symptoms, muscle weakness, smell/taste disorder and fatigue in Chinese people has been repeatedly evident by previous studies including Alpha strain, Delta strain and Omicron strain, even on a small scale or periods longer than one year[58–60].

Our study showed that long COVID-19 symptoms (such as rhinobyon/runny nose, fatigue and mood disorders) were associated with the age groups, which was consistent with prior study[6]. Therefore, it was well established that age was an important indicator for long COVID-19, but we had difficulty in comparing our results with prior studies due to different ranges of age group. Furthermore, data from Chinese population supported that both smoking and female were associated with an risk of fatigue, which was repeatedly reported by previous studies[32, 61–64]. These findings suggested an important clue to guiding future precise recovery management of long COVID-19 sequelae at 3 months.

To our knowledge, this is the largest study to date to firstly report on the symptom patterns of acute and long COVID-19 infection in Chinese mainland, during Omicron period. Strengths of the study include the use of a nationwide representative patients group, which is weighted by age ratios by gender from the Seventh National Census (2020 years) and is also validated by smoking rates from a prior study. The large sample size of over 30 thousand people provide enough statistical power to support stratified analyses. According to the data of the Chinese Center for Disease Control and Prevention, from September 26, 2022 to April 27, 2023, COVID-19 genome effective sequences of 43777 local cases in China mainland were Omicron variants, and all participants in our study was from October 1, 2022 to February 21, 2023[65]. Thus, our study could reflect the property of Omicron variant. However, there are several limitations. Firstly, to improve the accuracy of online survey data, we have limited age range to 25 to 65 years old, which limit the extrapolation of our findings. Secondly, only about 56% of infected patients was diagnosed by objective molecular tests, such as nucleic acid or antigen detection. In the early stages of the COVID-19 epidemic, limited medical resources could not meet testing needs of a large number of symptomatic individuals. In this study, the combination of symptoms and epidemiological history was also viewed as diagnostic criteria of COVID-19, which might bias our results. Thirdly, there may be health seeking bias in the self-reported symptom data, because some participants might be more active in maintaining their health and be more likely to report symptoms than others. Lastly, we also can not distinguish long COVID-19 symptoms from similar clinical manifestations that occur normally or following infections with other pathogens, but our main findings on long COVID-19 are consistent with other studies with a control group.

In conclusion, our findings indicated that omicron variant to be milder in terms of severity in China mainland and the long COVID-19 incidence at 3 months was 19.68% with main symptoms of muscle weakness, headache, smell/taste disorder and fatigue. In addition, current smokers and women had a higher proportion for each acute symptom, and were also associated with more number of symptoms during acute period. For long COVID-19, older age groups (45–54 and 55–65 years) were risk factors for rhinobyon/runny nose, fatigue and mood disorders, while female and smoking also increased an risk of fatigue. Therefore, under background of COVID-19 epidemic no longer listed as PHEIC, more attention should be given to high-risk population (current smokers, women, and the elderly) to control disease burden caused by COVID-19.

Ethics approval and consent to participate

Consent for publication

Not applicable as the manuscript contains no individual identifying data.

Availability of data and materials

Data sharing not applicable

Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding

This work was supported by National High Level Hospital Clinical Research Funding (2022-NHLHCRF-LX-01).

Author contributions

Conceptualization and design, CW and DX; Data collection, YHL, XMZ, YL, XX, QQS, JXL, RQ, ZL and LZ; Formal analysis, ZS, YX and ZXH; Writing - original draft, ZS and DX. All authors read and approved the final manuscript.

Acknowledgments

We would like to thank the countless participants of this COVID-19 study.

Data availability statement

All data in this study are not publicly available, but could be accessed by inquiring the corresponding author.

Coronavirus Disease WHO Coronavirus (COVID-19) Dashboard. [https://covid19.who.int/.]
Tracking SARS-CoV-2 variants. [https:/www.who.int/activities/tracking-SARS-CoV-2-variants.]
COVID-19: Variants of the Virus. [https://www.cdc.gov/coronavirus/2019-ncov/variants/variant.html.]
Taylor CA, Patel K, Pham H, Whitaker M, Anglin O, Kambhampati AK, Milucky J, Chai SJ, Kirley PD, Alden NB et al: Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance - COVID-NET, 14 States, January-August 2021. MMWR Morbidity and mortality weekly report 2021, 70(43):1513-1519.
Iuliano AD, Brunkard JM, Boehmer TK, Peterson E, Adjei S, Binder AM, Cobb S, Graff P, Hidalgo P, Panaggio MJ et al: Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022. MMWR Morbidity and mortality weekly report 2022, 71(4):146-152.
Mizrahi B, Sudry T, Flaks-Manov N, Yehezkelli Y, Kalkstein N, Akiva P, Ekka-Zohar A, Ben David SS, Lerner U, Bivas-Benita M et al: Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ (Clinical research ed) 2023, 380:e072529.
Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS et al: Post-acute COVID-19 syndrome. Nature medicine 2021, 27(4):601-615.
Blomberg B, Cox RJ, Langeland N: Long COVID: A growing problem in need of intervention. Cell reports Medicine 2022, 3(3):100552.
Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B: Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. The Journal of infectious diseases 2022, 226(9):1593-1607.
[https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic]
[https://covid.cdc.gov/covid-data-tracker/#trends_weeklydeaths_select_00]
Corona Virus Disease 2019 [https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/]
Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. [https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern]
Tracking of variants. [https://www.gisaid.org/hcov19-variants/]
Jassat W KS, Mudara C, et al.: Clinical severity of COVID-19 patients admitted to hospitals in Gauteng, South Africa during the omicron-dominant fourth wave. medRxiv : the preprint server for health sciences 2021.
Davies MA, Kassanjee R, Rosseau P, Morden E, Johnson L, Solomon W, Hsiao NY, Hussey H, Meintjes G, Paleker M et al: Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. medRxiv : the preprint server for health sciences 2022.
Houhamdi L, Gautret P, Hoang VT, Fournier PE, Colson P, Raoult D: Characteristics of the first 1119 SARS-CoV-2 Omicron variant cases, in Marseille, France, November-December 2021. Journal of medical virology 2022, 94(5):2290-2295.
Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B: Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves. Jama 2022, 327(6):583-584.
Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, Louca P, May A, Figueiredo JC, Hu C et al: Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet (London, England) 2022, 399(10335):1618-1624.
Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, Hinsley W, Bernal JL, Kall M, Bhatt S et al: Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet (London, England) 2022, 399(10332):1303-1312.
Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, Amoako DG, Everatt J, Bhiman JN, Scheepers C et al: Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet (London, England) 2022, 399(10323):437-446.
Risk for COVID-19 Infection, Hospitalization, and Death By Age Group. [https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html.]
Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19/infectionintheuk/3march2022.]
Bowyer RCE, Huggins C, Toms R, Shaw RJ, Hou B, Thompson EJ, Kwong ASF, Williams DM, Kibble M, Ploubidis GB et al: Characterising patterns of COVID-19 and long COVID symptoms: evidence from nine UK longitudinal studies. European journal of epidemiology 2023, 38(2):199-210.
Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, Noel A, Gunning S, Hatrick J, Hamilton S et al: Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax 2021, 76(4):399-401.
Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, Banerjee A: Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ (Clinical research ed) 2021, 372:n693.
Crook H, Raza S, Nowell J, Young M, Edison P: Long covid-mechanisms, risk factors, and management. BMJ (Clinical research ed) 2021, 374:n1648.
Daugherty SE, Guo Y, Heath K, Dasmariñas MC, Jubilo KG, Samranvedhya J, Lipsitch M, Cohen K: Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ (Clinical research ed) 2021, 373:n1098.
Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, Hu P, Guo L, Liu M, Xu J et al: 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet (London, England) 2021, 398(10302):747-758.
Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, Chu HY: Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA network open 2021, 4(2):e210830.
Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, O'Hara M, Suett J, Dahmash D, Bugaeva P et al: Characterising long COVID: a living systematic review. BMJ global health 2021, 6(9).
Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, Pujol JC, Klaser K, Antonelli M, Canas LS et al: Attributes and predictors of long COVID. Nature medicine 2021, 27(4):626-631.
Wu X, Liu X, Zhou Y, Yu H, Li R, Zhan Q, Ni F, Fang S, Lu Y, Ding X et al: 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. The Lancet Respiratory medicine 2021, 9(7):747-754.
Lu G, Ling Y, Jiang M, Tan Y, Wei D, Jiang L, Yu S, Jiang F, Wang S, Dai Y et al: Primary assessment of the diversity of Omicron sublineages and the epidemiologic features of autumn/winter 2022 COVID-19 wave in Chinese mainland. Frontiers of medicine 2023:1-10.
Notice on Issuing the Overall Plan for Implementing Class B Management for COVID- 19 Infection. [http://www.nhc.gov.cn/]
Notice on Further Optimizing Measures for the Prevention and Control of COVID-19 Epidemic and Scientifically and Precisely Carrying out Prevention and Control Work. [http://www.nhc.gov.cn/]
A clinical case defnition of post-COVID-19 condition by a Delphi consensus. [https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_defnition-2021.1]
Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H et al: Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ (Clinical research ed) 2020, 368:m1091.
Mangia C, Russo A, Civitelli S, Gianicolo EAL: Sex/gender differences in COVID-19 lethality: what the data say, and do not say. Epidemiologia e prevenzione 2020, 44(5-6 Suppl 2):400-406.
Spagnolo PA, Manson JE, Joffe H: Sex and Gender Differences in Health: What the COVID-19 Pandemic Can Teach Us. Annals of internal medicine 2020, 173(5):385-386.
Kim MK, Lee B, Choi YY, Um J, Lee KS, Sung HK, Kim Y, Park JS, Lee M, Jang HC et al: Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea. Journal of Korean medical science 2022, 37(3):e31.
Omicron spreads but severe cases remain low in South Africa. [https://www.afro.who.int/news/ omicron-spreads-severe-cases-remain-low-south-africa ]
Torjesen I: Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ (Clinical research ed) 2021, 375:n2943.
Transcription of the Press Conference of the State Council Joint Prevention and Control Mechanism [http://www.nhc.gov.cn/]
Liu K, He M, Zhuang Z, He D, Li H: Unexpected positive correlation between human development index and risk of infections and deaths of COVID-19 in Italy. One health (Amsterdam, Netherlands) 2020, 10:100174.
Luo J, Rizvi H, Preeshagul IR, Egger JV, Hoyos D, Bandlamudi C, McCarthy CG, Falcon CJ, Schoenfeld AJ, Arbour KC et al: COVID-19 in patients with lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology 2020, 31(10):1386-1396.
Li J, Long X, Zhang Q, Fang X, Li N, Fedorova B, Hu S, Li J, Xiong N, Lin Z: Tobacco smoking confers risk for severe COVID-19 unexplainable by pulmonary imaging. Journal of internal medicine 2021, 289(4):574-583.
Clift AK, von Ende A, Tan PS, Sallis HM, Lindson N, Coupland CAC, Munafò MR, Aveyard P, Hippisley-Cox J, Hopewell JC: Smoking and COVID-19 outcomes: an observational and Mendelian randomisation study using the UK Biobank cohort. Thorax 2022, 77(1):65-73.
Benowitz NL, Goniewicz ML, Halpern-Felsher B, Krishnan-Sarin S, Ling PM, O'Connor RJ, Pentz MA, Robertson RM, Bhatnagar A: Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19: current understanding and recommendations for future research. The Lancet Respiratory medicine 2022, 10(9):900-915.
Nyunoya T, Mebratu Y, Contreras A, Delgado M, Chand HS, Tesfaigzi Y: Molecular processes that drive cigarette smoke-induced epithelial cell fate of the lung. American journal of respiratory cell and molecular biology 2014, 50(3):471-482.
Self-reported long COVID after infection with the Omicron variant in the UK [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/selfreportedlongcovidafterinfectionwiththeomicronvariant/6may2022]
Gottlieb M, Wang R, Yu H, Spatz ES, Montoy JC, Rodriguez R, Chang AM, Elmore JG, Hannikainen PA, Hill M et al: Severe Fatigue and Persistent Symptoms at Three Months Following SARS-CoV-2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023.
Arjun MC, Singh AK, Pal D, Das K, G A, Venkateshan M, Mishra B, Patro BK, Mohapatra PR, Subba SH: Characteristics and predictors of Long COVID among diagnosed cases of COVID-19. PloS one 2022, 17(12):e0278825.
Arjun MC, Singh AK, Roy P, Ravichandran M, Mandal S, Pal D, Das K, Gajjala A, Venkateshan M, Mishra B et al: Long COVID following Omicron wave in Eastern India-A retrospective cohort study. Journal of medical virology 2023, 95(1):e28214.
Al-Aly Z, Bowe B, Xie Y: Long COVID after breakthrough SARS-CoV-2 infection. Nature medicine 2022, 28(7):1461-1467.
Strain WD, Sherwood O, Banerjee A, Van der Togt V, Hishmeh L, Rossman J: The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVID. Vaccines 2022, 10(5).
Taquet M, Dercon Q, Harrison PJ: Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. Brain, behavior, and immunity 2022, 103:154-162.
Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, Horn C, Vanshylla K, Cristanziano VD, Osebold L et al: Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. The Lancet regional health Europe 2021, 6:100122.
Blomberg B, Mohn KG, Brokstad KA, Zhou F, Linchausen DW, Hansen BA, Lartey S, Onyango TB, Kuwelker K, Sævik M et al: Long COVID in a prospective cohort of home-isolated patients. Nature medicine 2021, 27(9):1607-1613.
Lund LC, Hallas J, Nielsen H, Koch A, Mogensen SH, Brun NC, Christiansen CF, Thomsen RW, Pottegård A: Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. The Lancet Infectious diseases 2021, 21(10):1373-1382.
Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mulè G, Augello M, Mondatore D, Allegrini M, Cona A et al: Female gender is associated with long COVID syndrome: a prospective cohort study. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2022, 28(4):611.e619-611.e616.
Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, Li S, Hong S, Zhang R, Xie J et al: Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 2022, 185(5):881-895.e820.
Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, Taverner T, Chandan JS, Brown K, Simms-Williams N et al: Symptoms and risk factors for long COVID in non-hospitalized adults. Nature medicine 2022, 28(8):1706-1714.
Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, Ward H, Elliott P: Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nature communications 2022, 13(1):1957.
[https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202304/t20230429_265709.html]

No competing interests reported.

Supplementarymaterial.docx

Download PDF

Journal Publication

published 01 Aug, 2024

Read the published version in BMC Public Health →

Editorial decision: Revision requested
21 Feb, 2024
Reviews received at journal
14 Feb, 2024
Reviewers agreed at journal
04 Feb, 2024
Reviews received at journal
25 Nov, 2023
Reviews received at journal
19 Nov, 2023
Reviewers agreed at journal
12 Nov, 2023
Reviewers agreed at journal
29 Oct, 2023
Reviewers invited by journal
26 Oct, 2023
Editor assigned by journal
24 Oct, 2023
Editor invited by journal
24 Oct, 2023
Submission checks completed at journal
24 Oct, 2023
First submitted to journal
12 Oct, 2023

You are reading this latest preprint version

Female and smokers are associated with acute and long COVID-19 symptoms among 32,528 vaccination individuals: a cross-sectional and nationwide study from China

Status:

Journal Publication

Version 1

Abstract

Backgrounds

Methods

Results

Conclusions

Figures

Backgrounds

Methods

Study design

Study population

Ethical considerations

Variables

Statistical analysis

Results

Participants information

Clinical patterns and influencing factors among all acute COVID-19 patients

Relationship between age, sex, smoking status and severity of acute phase symptoms

Clinical patterns and influencing factors among long COVID-19 individuals

Discussion

Declarations

References

Additional Declarations

Supplementary Files

Status:

Journal Publication

Version 1